FINWIRES · TerminalLIVE
FINWIRES

Singapore's Private Sector Growth Accelerates in April Amid Record Demand

By

-- Singapore's private sector growth surged to its second-highest level since July 2022, driven by a record influx of new business.

The headline seasonally adjusted S&P Global Singapore Purchasing Managers' Index (PMI) rose to 57.9 in April from 56.7 in March, according to a report released Tuesday.

"The Singaporean private sector gained speed in April, with stronger growth in output and a record influx of new business signaled," S&P Global Market Intelligence economist Eleanor Dennison said. "April's demand injection meant that input requirements were greater and this triggered a record increase in buying activity."

New business accelerated due to a pick-up in domestic demand, offsetting the slowdown in export sales.

Ongoing tensions in the Middle East, which disrupted global oil supply, particularly in March, drove up prices and affected international demand for Singapore businesses.

Escalating oil prices also intensified cost pressures for local businesses, prompting most firms to pass the burden onto consumers by raising prices, according to S&P.

Companies reported accumulating backlogs as many trimmed jobs due to cost pressures.

"At a time of severely elevated inflationary pressures, firms therefore looked to cut costs where they could, which materialised as a reduction in employment levels," said Dennison.

Despite a drop in headcounts, business sentiment remained upbeat, with Singaporean companies' growth expectations currently at "their brightest on record," Dennison added.

Meanwhile, Singapore's retail sector remained resilient. Despite fluctuating fuel prices, strong vehicle sales continued to boost retail activity. Data from Statistics Singapore on Tuesday revealed a 4.8% year-over-year increase in retail sales in March, boosted by a 12.9% surge in motor vehicle and parts sales.

Singapore's first-quarter performance points to "resilient" consumer activity, supported by labor market conditions and tourism, Chua Han Teng, senior economist with Singapore-based DBS Bank said in a recent note, as per Singapore-based The Straits Times.

Related Articles

Asia

CuFe Completes Expanded Scoping Study at Northern Territory Project; Shares Jump 10%

CuFe (ASX:CUF) said an expanded scoping study on its 55%-owned Orlando project in the Northern Territory shows a net present value of around AU$705 million on a 100%-ownership basis, internal rate of return of 111%, and payback period of 10 months, according to a Wednesday Australian bourse filing.This improves to a net present value of around AU$908 million on a 100% ownership basis if spot prices as of April 8 are used, the company said.The Orlando project is part of the wider Orlando/Gecko project in which CuFe Tennant Creek holds a 55% stake and Gecko Mining, a subsidiary of Gold Valley Group, holds a 45% stake.The expanded study is based on a standalone development of the Orlando deposit, including the construction of a new processing plant, with plant purchase and installation costs of AU$86 million comprising the majority of the estimated AU$141 million total pre-production capital expenditure.The company is considering a cutback to the existing Orlando open pit, re-establishing underground operations and the installation of the plant capable of producing copper, gold, bismuth, and silver, per the filing.CuFe's shares rose past 10% in recent trading on Wednesday.

$ASX:CUF
Asia

SSY Group Receives China Approval for Three Drugs

Pharmaceutical firm SSY Group (HKG:2005) said it received drug production and registration approvals for three of its products in China, according to a Hong Kong bourse filing Wednesday.The approval from China's National Medical Products Administration covers a fat-soluble vitamin injection, metformin hydrochloride tablets for type 2 diabetes, and doxazosin mesylate extended release tablets for benign prostatic hyperplasia and hypertension.

$HKG:2005
Asia

Andon Health Plans to Sell Repurchased Shares

Andon Health (SHE:002432) plans to sell 9,295,000 repurchased shares through centralized bidding, according to a Wednesday disclosure on the Shenzhen bourse filing.The shares represent not more than 2% of the Chinese medical devices company's total share capital.The repurchased shares will be sold within six months.Proceeds from the sale will be used to fund business operations, including product research and development and technological investments.The company's shares fell 2% during recent trade.

$SHE:002432